Genetic/familial high-risk assessment: breast and ovarian.

Names: Lauren Corduck; Ephrat Levy-Lahad, MD; Ranjit Manchanda, MD, MRCOG, PhD; Jill Stopfer, MS, LGC; Elizabeth Etkin-Kramer, MD, FACOG; Patricia Clark, MD; Danielle Shiller, DO; Robin Straus Furlong, MD; Kimberly Deleonardis, MS, LGC Organizations: Oneinforty (www.oneinforty.org), Yodeah (www.yodeah.org) Address: Oneinforty, 17 Horseshoe Dr., Acton, MA 01720 Phone: 617-823-3630 Email: laurenc@oneinforty.org Date of request: April 24, 2019 NCCN Guideline Panel: Genetic/ Familial High-Risk Assessment: Breast and Ovarian

[1]  S. Cummings,et al.  NSGC Practice Guideline: Risk Assessment and Genetic Counseling for Hereditary Breast and Ovarian Cancer , 2013, Journal of Genetic Counseling.

[2]  D. Evans.  Are we ready for targeted early breast cancer detection strategies in women with NF1 aged 30–49 years? , 2012, American journal of medical genetics. Part A.

[3]  Paul Fockens,et al.  International Cancer of the Pancreas Screening (CAPS) Consortium summit on the management of patients with increased risk for familial pancreatic cancer , 2012, Gut.

[4]  Elisabeth Cardis,et al.  Exposure to diagnostic radiation and risk of breast cancer among carriers of BRCA1/2 mutations: retrospective cohort study (GENE-RAD-RISK) , 2012, BMJ : British Medical Journal.

[5]  D. Huntsman,et al.  Germline BRCA1 and BRCA2 Mutations in Ovarian Cancer: Utility of a Histology-Based Referral Strategy , 2012, Obstetrics and gynecology.

[6]  S. Narod,et al.  Routine TP53 testing for breast cancer under age 30: ready for prime time? , 2012, Familial Cancer.

[7]  J. George,et al.  BRCA mutation frequency and patterns of treatment response in BRCA mutation-positive women with ovarian cancer: a report from the Australian Ovarian Cancer Study Group. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[8]  A. Al-Niaimi,et al.  Epithelial ovarian cancer. , 2012, Obstetrics and gynecology clinics of North America.

[9]  W. Eiermann,et al.  BRCA2 Mutations and Triple-Negative Breast Cancer , 2012, PloS one.

[10]  M. Yaffe,et al.  Long-term results of screening with magnetic resonance imaging in women with BRCA mutations , 2012, British Journal of Cancer.

[11]  A. Meindl,et al.  Germline RAD51C mutations confer susceptibility to ovarian cancer , 2012, Nature Genetics.

[12]  D. Easton,et al.  Germline BRCA1 mutations increase prostate cancer risk , 2012, British Journal of Cancer.

[13]  C. Gatsonis,et al.  Annual screening strategies in BRCA1 and BRCA2 gene mutation carriers , 2012, Cancer.

[14]  F. Fostira,et al.  Prevalence of BRCA1 mutations among 403 women with triple-negative breast cancer: implications for genetic screening selection criteria: a Hellenic Cooperative Oncology Group Study , 2012, Breast Cancer Research and Treatment.

[15]  Diane D. Liu,et al.  Early onset HER2‐positive breast cancer is associated with germline TP53 mutations , 2012, Cancer.

[16]  Gord Glendon,et al.  Association Between BRCA1 and BRCA2 Mutations and Survival in Women With Invasive Epithelial Ovarian Cancer , 2012 .

[17]  G. Hortobagyi,et al.  Earlier age of onset of BRCA mutation‐related cancers in subsequent generations , 2012, Cancer.

[18]  K. Offit,et al.  Prevalence of BRCA1 and BRCA2 mutations in Ashkenazi Jewish families with breast and pancreatic cancer , 2012, Cancer.

[19]  C. Eng,et al.  Lifetime Cancer Risks in Individuals with Germline PTEN Mutations , 2012, Clinical Cancer Research.

[20]  N. Leslie,et al.  GeneReviews at GeneTests Medical Genetics Information Resource (Database Online) , 2012 .

[21]  Erika L. Varner,et al.  Evaluation of BRCA1 mutations in an unselected patient population with triple-negative breast cancer , 2012, Breast Cancer Research and Treatment.

[22]  Sofia Khan,et al.  Risk of cancer other than breast or ovarian in individuals with BRCA1 and BRCA2 mutations , 2012, Familial Cancer.

[23]  S. Teo,et al.  Comparable frequency of BRCA1, BRCA2 and TP53 germline mutations in a multi-ethnic Asian cohort suggests TP53 screening should be offered together with BRCA1/2 screening to early-onset breast cancer patients , 2012, Breast Cancer Research.

[24]  L. Bernstein,et al.  Characteristics of triple-negative breast cancer in patients with a BRCA1 mutation: results from a population-based study of young women. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[25]  A. Gylfason,et al.  Mutations in BRIP1 confer high risk of ovarian cancer , 2011, Nature Genetics.

[26]  Alan D. Lopez,et al.  Breast and cervical cancer in 187 countries between 1980 and 2010: a systematic analysis , 2011, The Lancet.

[27]  Rochelle L. Garcia,et al.  Mutations in 12 genes for inherited ovarian, fallopian tube, and peritoneal carcinoma identified by massively parallel sequencing , 2011, Proceedings of the National Academy of Sciences.

[28]  K. Hess,et al.  Association of BRCA1 and BRCA2 mutations with survival, chemotherapy sensitivity, and gene mutator phenotype in patients with ovarian cancer. , 2011, JAMA.

[29]  A. Jakubowska,et al.  Risk of breast cancer in women with a CHEK2 mutation with and without a family history of breast cancer. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[30]  H. Mackay,et al.  Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-label, non-randomised study. , 2011, The Lancet. Oncology.

[31]  Julie O. Culver,et al.  Genetics, genomics, and cancer risk assessment , 2011, CA: a cancer journal for clinicians.

[32]  G. Hortobagyi,et al.  Effectiveness of alternating mammography and magnetic resonance imaging for screening women with deleterious BRCA mutations at high risk of breast cancer , 2011, Cancer.

[33]  Deborah Hughes,et al.  Germline mutations in RAD51D confer susceptibility to ovarian cancer , 2011, Nature Genetics.

[34]  P. Oefner,et al.  Rare variants in the ATM gene and risk of breast cancer , 2011, Breast Cancer Research.

[35]  S. Schnitt,et al.  Clinical outcome of triple negative breast cancer in BRCA1 mutation carriers and noncarriers , 2011, Cancer.

[36]  J. Fraumeni,et al.  Gastric cancer in individuals with Li-Fraumeni syndrome , 2011, Genetics in Medicine.

[37]  S. Fox,et al.  The Dawn of a Revolution in Personalized Lung Cancer Prevention , 2011, Cancer Prevention Research.

[38]  T. Prior,et al.  Predicting PTEN mutations: an evaluation of Cowden syndrome and Bannayan–Riley–Ruvalcaba syndrome clinical features , 2011, Journal of Medical Genetics.

[39]  Laetitia Huiart,et al.  Cancer risks associated with germline mutations in MLH1, MSH2, and MSH6 genes in Lynch syndrome. , 2011, JAMA.

[40]  A. Howell,et al.  Prevalence of BRCA1 and BRCA2 mutations in triple negative breast cancer , 2011, Journal of Medical Genetics.

[41]  J. Beyene,et al.  Biochemical and imaging surveillance in germline TP53 mutation carriers with Li-Fraumeni syndrome: a prospective observational study. , 2011, The Lancet. Oncology.

[42]  M. Goetz,et al.  Colonic polyposis and neoplasia in Cowden syndrome. , 2011, Mayo Clinic proceedings.

[43]  J. Bayley.  Succinate dehydrogenase gene variants and their role in Cowden syndrome. , 2011, American journal of human genetics.

[44]  A. Auranen,et al.  A systematic review of gynecological cancer surveillance in women belonging to hereditary nonpolyposis colorectal cancer (Lynch syndrome) families , 2011, Acta obstetricia et gynecologica Scandinavica.

[45]  Barry Rosen,et al.  Frequencies of BRCA1 and BRCA2 mutations among 1,342 unselected patients with invasive ovarian cancer. , 2011, Gynecologic oncology.

[46]  Wei Zheng,et al.  Genetic variants associated with breast-cancer risk: comprehensive research synopsis, meta-analysis, and epidemiological evidence. , 2011, The Lancet. Oncology.

[47]  T. Walsh,et al.  Contribution of inherited mutations in the BRCA2-interacting protein PALB2 to familial breast cancer. , 2011, Cancer research.

[48]  C. Hudis,et al.  Relative contributions of BRCA1 and BRCA2 mutations to “triple-negative” breast cancer in Ashkenazi Women , 2011, Breast Cancer Research and Treatment.

[49]  J. Schleutker,et al.  Screening for BRCA1, BRCA2, CHEK2, PALB2, BRIP1, RAD50, and CDH1 mutations in high-risk Finnish BRCA1/2-founder mutation-negative breast and/or ovarian cancer individuals , 2011, Breast Cancer Research.

[50]  C. Curiel-Lewandrowski,et al.  Multiple primary cutaneous melanomas in Li-Fraumeni syndrome. , 2011, Archives of dermatology.

[51]  G. Mills,et al.  Incidence and Outcome of BRCA Mutations in Unselected Patients with Triple Receptor-Negative Breast Cancer , 2011, Clinical Cancer Research.

[52]  Charis Eng,et al.  A clinical scoring system for selection of patients for PTEN mutation testing is proposed on the basis of a prospective study of 3042 probands. , 2011, American journal of human genetics.

[53]  D. Malkin.  Li-fraumeni syndrome. , 2001, Genes & cancer.

[54]  C. Iavazzo,et al.  Endometrial carcinoma and ovarian sex cord tumor with annular tubules in a patient with history of Peutz-Jeghers syndrome and multiple malignancies. , 2011, European journal of gynaecological oncology.

[55]  S. Neuhausen,et al.  Mutations in BRCA2 and PALB2 in male breast cancer cases from the United States , 2011, Breast Cancer Research and Treatment.

[56]  C. Eng,et al.  Germline epigenetic regulation of KILLIN in Cowden and Cowden-like syndrome. , 2010, JAMA.

[57]  C. Eng,et al.  Frequent gastrointestinal polyps and colorectal adenocarcinomas in a prospective series of PTEN mutation carriers. , 2010, Gastroenterology.

[58]  J. Douglas,et al.  Absence of CHEK2*1100delC mutation in families with hereditary breast cancer in North America. , 2010, Cancer genetics and cytogenetics.

[59]  S. Friedman,et al.  High risk men's perceptions of pre-implantation genetic diagnosis for hereditary breast and ovarian cancer. , 2010, Human reproduction.

[60]  Bing Xia,et al.  PALB2/FANCN: recombining cancer and Fanconi anemia. , 2010, Cancer research.

[61]  N. Rahman,et al.  A novel HER2-positive breast cancer phenotype arising from germline TP53 mutations , 2010, Journal of Medical Genetics.

[62]  B. Bonanni,et al.  Oral contraceptive use and breast or ovarian cancer risk in BRCA1/2 carriers: a meta-analysis. , 2010, European journal of cancer.

[63]  A. Tutt,et al.  Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial , 2010, The Lancet.

[64]  D. Evans,et al.  Risk of breast cancer in male BRCA2 carriers , 2010, Journal of Medical Genetics.

[65]  T. Walsh,et al.  Detection of inherited mutations for breast and ovarian cancer using genomic capture and massively parallel sequencing , 2010, Proceedings of the National Academy of Sciences.

[66]  L. Boardman,et al.  Cancer and Lhermitte-Duclos disease are common in Cowden syndrome patients , 2010, Hereditary cancer in clinical practice.

[67]  T. Byers,et al.  Population-based estimate of the contribution of TP53 mutations to subgroups of early-onset breast cancer: Australian Breast Cancer Family Study. , 2010, Cancer research.

[68]  J. Baselga,et al.  High prevalence of BRCA1/2 germline mutations in female breast cancer patients with triple-negative phenotype (TNBC) and family history. , 2010 .

[69]  Jan Lubinski,et al.  Poly(ADP)-ribose polymerase inhibition: frequent durable responses in BRCA carrier ovarian cancer correlating with platinum-free interval. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[70]  Joseph P. Costantino,et al.  Update of the National Surgical Adjuvant Breast and Bowel Project Study of Tamoxifen and Raloxifene (STAR) P-2 Trial: Preventing Breast Cancer , 2010, Cancer Prevention Research.

[71]  P. Scardino,et al.  Germline BRCA Mutations Denote a Clinicopathologic Subset of Prostate Cancer , 2010, Clinical Cancer Research.

[72]  S. Narod,et al.  Screening for founder mutations in BRCA1 and BRCA2 in unselected Jewish women. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[73]  A. Børresen-Dale,et al.  Radiation exposure, the ATM Gene, and contralateral breast cancer in the women's environmental cancer and radiation epidemiology study. , 2010, Journal of the National Cancer Institute.

[74]  J. Charrow,et al.  Neurofibromatosis type 1 and high-grade tumors of the central nervous system , 2010, Child's Nervous System.

[75]  Jukka-Pekka Mecklin,et al.  Ten years after mutation testing for Lynch syndrome: cancer incidence and outcome in mutation-positive and mutation-negative family members. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[76]  C. Eng,et al.  PTEN hamartoma tumor syndrome: An overview , 2009, Genetics in Medicine.

[77]  S. Friedman,et al.  Factors associated with preimplantation genetic diagnosis acceptance among women concerned about hereditary breast and ovarian cancer , 2009, Genetics in Medicine.

[78]  Catherine Bonaïti-Pellié,et al.  2009 version of the Chompret criteria for Li Fraumeni syndrome. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[79]  Z. Aziz,et al.  The prevalence of germ-line TP53 mutations in women diagnosed with breast cancer before age 30 , 2009, Familial Cancer.

[80]  Lindsey M. King,et al.  Conflict between values and technology: perceptions of preimplantation genetic diagnosis among women at increased risk for hereditary breast and ovarian cancer , 2009, Familial Cancer.

[81]  P. Shaw,et al.  Candidate serous cancer precursors in fallopian tube epithelium of BRCA1/2 mutation carriers , 2009, Modern Pathology.

[82]  Lindsey M. King,et al.  Attitudes of high-risk women toward preimplantation genetic diagnosis. , 2009, Fertility and sterility.

[83]  Maximina H. Yun,et al.  Understanding the functions of BRCA1 in the DNA-damage response. , 2009, Biochemical Society transactions.

[84]  M. Werner,et al.  Preimplantation genetic diagnosis for BRCA1/2—a novel clinical experience , 2009, Prenatal diagnosis.

[85]  Matthew Burnell,et al.  Sensitivity and specificity of multimodal and ultrasound screening for ovarian cancer, and stage distribution of detected cancers: results of the prevalence screen of the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS) , 2009, Journal of Family Planning and Reproductive Health Care.

[86]  A. Godwin,et al.  Hereditary ovarian carcinoma: Heterogeneity, molecular genetics, pathology, and management , 2009, Molecular oncology.

[87]  S. Sommer,et al.  Beyond Li Fraumeni Syndrome: clinical characteristics of families with p53 germline mutations. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[88]  J. Fandino,et al.  Lhermitte-Duclos disease with atypical vascularization--case report and review of the literature. , 2009, Clinical neuropathology.

[89]  A. Barkun,et al.  A case of Cowden's syndrome presenting with gastric carcinomas and gastrointestinal polyposis , 2009, Nature Clinical Practice Gastroenterology &Hepatology.

[90]  V. Sorrentino,et al.  Novel PTEN mutations in neurodevelopmental disorders and macrocephaly , 2009, Clinical genetics.

[91]  K. McBride,et al.  The prevalence of PTEN mutations in a clinical pediatric cohort with autism spectrum disorders, developmental delay, and macrocephaly , 2009, Genetics in Medicine.

[92]  Ilir Agalliu,et al.  Associations of High-Grade Prostate Cancer with BRCA1 and BRCA2 Founder Mutations , 2009, Clinical Cancer Research.

[93]  Laura H. Tang,et al.  BRCA germline mutations in Jewish patients with pancreatic adenocarcinoma. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[94]  M. Morrow,et al.  Prophylactic mastectomy and the timing of breast reconstruction , 2009, The British journal of surgery.

[95]  P. Branton,et al.  Protocol for the Examination of Specimens from Patients with Carcinoma of the Vulva , 2009 .

[96]  P. Goodwin,et al.  Prognosis of BRCA-associated breast cancer: a summary of evidence , 2009, Breast Cancer Research and Treatment.

[97]  Stephanie A Cohen,et al.  The prevalence of BRCA1 mutations among young women with triple-negative breast cancer , 2009, BMC Cancer.

[98]  R. Pilarski.  Cowden Syndrome: A Critical Review of the Clinical Literature , 2009, Journal of Genetic Counseling.

[99]  R. Eeles,et al.  "BRCAness" syndrome in ovarian cancer: a case-control study describing the clinical features and outcome of patients with epithelial ovarian cancer associated with BRCA1 and BRCA2 mutations. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[100]  Barbara L. Smith,et al.  The American Cancer Society guidelines for breast screening with magnetic resonance imaging , 2008, Cancer.

[101]  W. Foulkes,et al.  Inherited susceptibility to common cancers. , 2008, The New England journal of medicine.

[102]  Richard G. Moore,et al.  A Case of Peutz-Jeghers Syndrome With Breast Cancer, Bilateral Sex Cord Tumor With Annular Tubules, and Adenoma Malignum Caused by STK11 Gene Mutation , 2008, International Journal of Gynecologic Cancer.

[103]  B. Henderson,et al.  Effect of Reproductive Factors and Oral Contraceptives on Breast Cancer Risk in BRCA1/2 Mutation Carriers and Noncarriers: Results from a Population-Based Study , 2008, Cancer Epidemiology Biomarkers & Prevention.

[104]  R. Prentice,et al.  Menopausal hormone therapy in BRCA1 mutation carriers: uncertainty and caution. , 2008, Journal of the National Cancer Institute.

[105]  J. Apffelstaedt,et al.  Counseling for male BRCA mutation carriers: a review. , 2008, Breast.

[106]  J. Klijn,et al.  Hormone Therapy and the Risk of Breast Cancer in BRCA1 Mutation Carriers , 2008, Journal of the National Cancer Institute.

[107]  C. Eng,et al.  Genetic and phenotypic heterogeneity in the PTEN hamartoma tumour syndrome , 2008, Oncogene.

[108]  D. L. Doyle,et al.  Standardized Human Pedigree Nomenclature: Update and Assessment of the Recommendations of the National Society of Genetic Counselors , 2008, Journal of Genetic Counseling.

[109]  Christopher I Amos,et al.  Clinical and pathologic characteristics of patients with BRCA-positive and BRCA-negative breast cancer. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[110]  T. Rebbeck,et al.  The relative contribution of point mutations and genomic rearrangements in BRCA1 and BRCA2 in high-risk breast cancer families. , 2008, Cancer research.

[111]  K. Calzone,et al.  Genetic testing for cancer susceptibility. , 2008, The Surgical clinics of North America.

[112]  J. Mecklin,et al.  The risk of extra‐colonic, extra‐endometrial cancer in the Lynch syndrome , 2008, International journal of cancer.

[113]  P Ghadirian,et al.  Rapid progression of prostate cancer in men with a BRCA2 mutation , 2008, British Journal of Cancer.

[114]  C. Bonaïti‐pellié,et al.  Molecular basis of the Li–Fraumeni syndrome: an update from the French LFS families , 2008, Journal of Medical Genetics.

[115]  W. Otten,et al.  Decision making regarding prophylactic mastectomy: stability of preferences and the impact of anticipated feelings of regret. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[116]  F. Chibon,et al.  Contribution of PTEN large rearrangements in Cowden disease: a multiplex amplifiable probe hybridisation (MAPH) screening approach , 2008, Journal of Medical Genetics.

[117]  S. Sanjosé,et al.  ATM germline mutations in Spanish early‐onset breast cancer patients negative for BRCA1/BRCA2 mutations , 2008, Clinical genetics.

[118]  P. Møller,et al.  Screening for familial ovarian cancer: poor survival of BRCA1/2 related cancers , 2008, Journal of Medical Genetics.

[119]  R. Eeles,et al.  Predicting the likelihood of carrying a BRCA1 or BRCA2 mutation: validation of BOADICEA, BRCAPRO, IBIS, Myriad and the Manchester scoring system using data from UK genetics clinics , 2008, Journal of Medical Genetics.

[120]  J. Liebelt,et al.  Preimplantation genetic diagnosis for BRCA1 exon 13 duplication mutation using linked polymorphic markers resulting in a live birth , 2008, Prenatal diagnosis.

[121]  T. Dörk,et al.  Nijmegen Breakage Syndrome mutations and risk of breast cancer , 2008, International journal of cancer.

[122]  S. Bojesen,et al.  CHEK2*1100delC genotyping for clinical assessment of breast cancer risk: meta-analyses of 26,000 patient cases and 27,000 controls. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[123]  V. Beral,et al.  Ovarian cancer and oral contraceptives: collaborative reanalysis of data from 45 epidemiological studies including 23 257 women with ovarian cancer and 87 303 controls , 2008, The Lancet.

[124]  R. Eeles,et al.  Prostate cancer in male BRCA1 and BRCA2 mutation carriers has a more aggressive phenotype , 2008, British Journal of Cancer.

[125]  R. Simon,et al.  On the dynamics of breast tumor development in women carrying germline BRCA1 and BRCA2 mutations , 2007, International journal of cancer.

[126]  L. Forétova,et al.  A rare tumor and an ethical dilemma in a family with a germline TP53 mutation. , 2008, Cancer genetics and cytogenetics.

[127]  E. Friedman,et al.  Effect of BRCA1/2 mutations on long-term survival of patients with invasive ovarian cancer: the national Israeli study of ovarian cancer. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[128]  M. Beattie,et al.  Prevalence and characteristics of pancreatic cancer in families with BRCA1 and BRCA2 mutations , 2008, Familial Cancer.

[129]  P. Spellman,et al.  Ovarian carcinomas with genetic and epigenetic BRCA1 loss have distinct molecular abnormalities , 2008, BMC Cancer.

[130]  Giovanni Parmigiani,et al.  Breast cancer risk among male BRCA1 and BRCA2 mutation carriers. , 2007, Journal of the National Cancer Institute.

[131]  E. Woodward,et al.  Annual surveillance by CA125 and transvaginal ultrasound for ovarian cancer in both high‐risk and population risk women is ineffective , 2007, BJOG : an international journal of obstetrics and gynaecology.

[132]  Janine Senz,et al.  Hereditary diffuse gastric cancer: association with lobular breast cancer , 2007, Familial Cancer.

[133]  C. Tzeng,et al.  Hair follicle: a reliable source of recipient origin after allogeneic hematopoietic stem cell transplantation , 2007, Bone Marrow Transplantation.

[134]  T. Helbich,et al.  Magnetic Resonance Imaging of the Breast Improves Detection of Invasive Cancer, Preinvasive Cancer, and Premalignant Lesions during Surveillance of Women at High Risk for Breast Cancer , 2007, Clinical Cancer Research.

[135]  Ross S Berkowitz,et al.  Primary fallopian tube malignancies in BRCA-positive women undergoing surgery for ovarian cancer risk reduction. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[136]  C. Eng,et al.  Hamartomatous polyposis syndromes , 2007, Nature Clinical Practice Gastroenterology &Hepatology.

[137]  G. Tomlinson,et al.  Evidence for Common Ancestral Origin of a Recurring BRCA1 Genomic Rearrangement Identified in High-Risk Hispanic Families , 2007, Cancer Epidemiology Biomarkers & Prevention.

[138]  P. Miron,et al.  Germline E-cadherin mutations in familial lobular breast cancer , 2007, Journal of Medical Genetics.

[139]  A. Caughey,et al.  Gynecologic Cancer Prevention in Lynch Syndrome/Hereditary Nonpolyposis Colorectal Cancer Families , 2007, Obstetrics and gynecology.

[140]  Thorunn Rafnar,et al.  Prostate cancer progression and survival in BRCA2 mutation carriers. , 2007, Journal of the National Cancer Institute.

[141]  Julie O. Culver,et al.  Limited family structure and BRCA gene mutation status in single cases of breast cancer. , 2007, JAMA.

[142]  B. Fernandez,et al.  Founder and recurrent CDH1 mutations in families with hereditary diffuse gastric cancer. , 2007, JAMA.

[143]  I. Jacobs,et al.  Views of BRCA gene mutation carriers on preimplantation genetic diagnosis as a reproductive option for hereditary breast and ovarian cancer. , 2007, Human reproduction.

[144]  J. Berliner,et al.  Risk Assessment and Genetic Counseling for Hereditary Breast and Ovarian Cancer: Recommendations of the National Society of Genetic Counselors , 2007, Journal of Genetic Counseling.

[145]  K. McBride,et al.  Genetic testing in autism: how much is enough? , 2007, Genetics in Medicine.

[146]  Giovanni Parmigiani,et al.  Meta-analysis of BRCA1 and BRCA2 penetrance. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[147]  D. Evans,et al.  Women with neurofibromatosis 1 are at a moderately increased risk of developing breast cancer and should be considered for early screening , 2007, Journal of Medical Genetics.

[148]  Eric Butter,et al.  Increasing knowledge of PTEN germline mutations: Two additional patients with autism and macrocephaly , 2007, American journal of medical genetics. Part A.

[149]  Laura Cortesi,et al.  Multicenter comparative multimodality surveillance of women at genetic-familial high risk for breast cancer (HIBCRIT study): interim results. , 2007, Radiology.

[150]  M. Yaffe,et al.  American Cancer Society Guidelines for Breast Screening with MRI as an Adjunct to Mammography , 2007, CA: a cancer journal for clinicians.

[151]  J. Mecklin,et al.  Surveillance for endometrial cancer in hereditary nonpolyposis colorectal cancer syndrome , 2007, International journal of cancer.

[152]  R. Berkowitz,et al.  Intraepithelial Carcinoma of the Fimbria and Pelvic Serous Carcinoma: Evidence for a Causal Relationship , 2007, The American journal of surgical pathology.

[153]  D. Evans,et al.  Guidelines for the diagnosis and management of individuals with neurofibromatosis 1 , 2006, Journal of Medical Genetics.

[154]  D. Fishman,et al.  Reproductive risk factors for ovarian cancer in carriers of BRCA1 or BRCA2 mutations: a case-control study. , 2007, The Lancet. Oncology.

[155]  Validity of Models for Predicting BRCA1 and BRCA2 Mutations , 2007, Annals of Internal Medicine.

[156]  P. Møller,et al.  The risk of endometrial cancer in women with BRCA1 and BRCA2 mutations. A prospective study. , 2007, Gynecologic oncology.

[157]  L. Esserman,et al.  Genetic/familial high-risk assessment , 2010 .

[158]  K. Offit,et al.  Preimplantation genetic diagnosis for cancer syndromes: a new challenge for preventive medicine. , 2006, JAMA.

[159]  Barry Rosen,et al.  Population BRCA1 and BRCA2 mutation frequencies and cancer penetrances: a kin-cohort study in Ontario, Canada. , 2006, Journal of the National Cancer Institute.

[160]  K. Offit,et al.  Effect of Mammography on Breast Cancer Risk in Women with Mutations in BRCA1 or BRCA2 , 2006, Cancer Epidemiology Biomarkers & Prevention.

[161]  K. Offit,et al.  Cancer genetic testing and assisted reproduction. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[162]  A. Whittemore,et al.  BRCA1 and BRCA2 Mutation Carriers, Oral Contraceptive Use, and Breast Cancer Before Age 50 , 2006, Cancer Epidemiology Biomarkers & Prevention.

[163]  G. Petersen,et al.  Recommendations for the care of individuals with an inherited predisposition to Lynch syndrome: a systematic review. , 2006, JAMA.

[164]  S. Cummings,et al.  Effect of Raloxifene on the Incidence of Invasive Breast Cancer in Postmenopausal Women with Osteoporosis Categorized by Breast Cancer Risk , 2006, Clinical Cancer Research.

[165]  K. Hemminki,et al.  Familial risk for histology-specific bone cancers: an updated study in Sweden. , 2006, European journal of cancer.

[166]  A. Børresen-Dale,et al.  ATM variants and cancer risk in breast cancer patients from Southern Finland , 2006, BMC Cancer.

[167]  L. Cipak,et al.  The role of BRCA2 in replication-coupled DNA interstrand cross-link repair in vitro , 2006, Nature Structural &Molecular Biology.

[168]  A. Kluska,et al.  Germline mutations 657del5 of the NBS1 gene contribute significantly to the incidence of breast cancer in Central Poland , 2006, International journal of cancer.

[169]  F. Couch,et al.  Salpingo-oophorectomy and the risk of ovarian, fallopian tube, and peritoneal cancers in women with a BRCA1 or BRCA2 Mutation. , 2006, JAMA.

[170]  Norman Wolmark,et al.  Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial. , 2006, JAMA.

[171]  D. Easton,et al.  A prospective study of neurofibromatosis type 1 cancer incidence in the UK , 2006, British Journal of Cancer.

[172]  S. Gruber,et al.  Frequency and Spectrum of Cancers in the Peutz-Jeghers Syndrome , 2006, Clinical Cancer Research.

[173]  P. Møller,et al.  Screening mammography and risk of breast cancer in BRCA1 and BRCA2 mutation carriers: a case-control study. , 2006, The Lancet. Oncology.

[174]  O. Olopade,et al.  Tamoxifen and contralateral breast cancer in BRCA1 and BRCA2 carriers: An update , 2006, International journal of cancer.

[175]  Andrew Shenton,et al.  BRCA1, BRCA2 and TP53 mutations in very early-onset breast cancer with associated risks to relatives. , 2006, European journal of cancer.

[176]  S. Orlow,et al.  Mucocutaneous neuromas: an underrecognized manifestation of PTEN hamartoma-tumor syndrome. , 2006, Archives of dermatology.

[177]  T. Walsh,et al.  Spectrum of mutations in BRCA1, BRCA2, CHEK2, and TP53 in families at high risk of breast cancer. , 2006, JAMA.

[178]  Christopher P Crum,et al.  The Tubal Fimbria Is a Preferred Site for Early Adenocarcinoma in Women With Familial Ovarian Cancer Syndrome , 2006, The American journal of surgical pathology.

[179]  M. Munsell,et al.  Prophylactic surgery to reduce the risk of gynecologic cancers in the Lynch syndrome. , 2006, The New England journal of medicine.

[180]  D. Easton,et al.  Genetic Linkage Analysis in Familial Breast and Ovarian Cancer: Results from 214 Families , 2006 .

[181]  M. Morrow,et al.  Appropriateness of Breast-Conserving Treatment of Breast Carcinoma in Women With Germline Mutations in BRCA1 or BRCA2: A Clinic-Based SeriesRobson M, Svahn T, McCormick B, et al (Mem Sloan-Kettering Cancer Ctr, New York) Cancer 103:44-51, 2005§ , 2006 .

[182]  G. Collins.  The next generation. , 2006, Scientific American.

[183]  T. Colgan,et al.  Clinical and pathologic findings of prophylactic salpingo-oophorectomies in 159 BRCA1 and BRCA2 carriers. , 2006, Gynecologic oncology.

[184]  J. Krischer,et al.  BRCA1 and BRCA2 mutations account for a large proportion of ovarian carcinoma cases , 2005, Cancer.

[185]  R. Fimmers,et al.  Mammography, breast ultrasound, and magnetic resonance imaging for surveillance of women at high familial risk for breast cancer. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[186]  O. Olopade,et al.  Effect of short-term hormone replacement therapy on breast cancer risk reduction after bilateral prophylactic oophorectomy in BRCA1 and BRCA2 mutation carriers: the PROSE Study Group. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[187]  C. Bonaïti‐pellié,et al.  Impact of the MDM2 SNP309 and p53 Arg72Pro polymorphism on age of tumour onset in Li-Fraumeni syndrome , 2005, Journal of Medical Genetics.

[188]  T. Rebbeck,et al.  Breast cancer risk following bilateral oophorectomy in BRCA1 and BRCA2 mutation carriers: an international case-control study. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[189]  Nandita Mitra,et al.  Risk of ovarian cancer in BRCA1 and BRCA2 mutation-negative hereditary breast cancer families. , 2005, Journal of the National Cancer Institute.

[190]  J. C. Houwelingen,et al.  Cancer risks in BRCA2 families: estimates for sites other than breast and ovary , 2005, Journal of Medical Genetics.

[191]  R. Winqvist,et al.  Association of common ATM polymorphism with bilateral breast cancer , 2005, International journal of cancer.

[192]  Julian Peto,et al.  Prediction of BRCA1 Status in Patients with Breast Cancer Using Estrogen Receptor and Basal Phenotype , 2005, Clinical Cancer Research.

[193]  M. Trková,et al.  Identification of five new families strengthens the link between childhood choroid plexus carcinoma and germline TP53 mutations. , 2005, European journal of cancer.

[194]  C. Hudis,et al.  Four-year follow-up of outcomes following risk-reducing salpingo-oophorectomy in BRCA mutation carriers , 2005 .

[195]  P. Oefner,et al.  Two ATM variants and breast cancer risk , 2005, Human mutation.

[196]  A R Padhani,et al.  Screening with magnetic resonance imaging and mammography of a UK population at high familial risk of breast cancer: a prospective multicentre cohort study (MARIBS) , 2005, The Lancet.

[197]  R. Brand,et al.  BRCA1 and pancreatic cancer: pedigree findings and their causal relationships. , 2005, Cancer genetics and cytogenetics.

[198]  C Eng,et al.  Subset of individuals with autism spectrum disorders and extreme macrocephaly associated with germline PTEN tumour suppressor gene mutations , 2005, Journal of Medical Genetics.

[199]  R. Young,et al.  Sex cord-stromal tumors of the ovary and testis: their similarities and differences with consideration of selected problems , 2005, Modern Pathology.

[200]  A. Whittemore,et al.  Oral Contraceptive Use and Risk of Early-Onset Breast Cancer in Carriers and Noncarriers of BRCA1 and BRCA2 Mutations , 2005, Cancer Epidemiology Biomarkers & Prevention.

[201]  H. Lynch,et al.  Clinical/genetic features in hereditary breast cancer , 1990, Breast Cancer Research and Treatment.

[202]  M. Beattie,et al.  Risk-reducing salpingo-oophorectomy in BRCA mutation carriers: role of serial sectioning in the detection of occult malignancy. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[203]  K. Offit,et al.  Evaluation of germline PTEN mutations in endometrial cancer patients. , 2005, Gynecologic oncology.

[204]  A. Jemal,et al.  Cancer Statistics, 2005 , 2005, CA: a cancer journal for clinicians.

[205]  K. Offit,et al.  The TP53 mutational spectrum and frequency of CHEK2*1100delC in Li–Fraumeni-like kindreds , 2005, Familial Cancer.

[206]  H. Nevanlinna,et al.  Relationship of patients' age to histopathological features of breast tumours in BRCA1 and BRCA2 and mutation-negative breast cancer families , 2005, Breast Cancer Research.

[207]  K. Hemminki,et al.  Risk of cancer at sites other than the breast in Swedish families eligible for BRCA1 or BRCA2 mutation testing. , 2004, Annals of oncology : official journal of the European Society for Medical Oncology.

[208]  S. Cummings,et al.  Continuing outcomes relevant to Evista: breast cancer incidence in postmenopausal osteoporotic women in a randomized trial of raloxifene. , 2004, Journal of the National Cancer Institute.

[209]  E. Hovig,et al.  BRCA1 mutations in ovarian cancer and borderline tumours in Norway: a nested case–control study , 2004, British Journal of Cancer.

[210]  Emily White,et al.  Factors contributing to mammography failure in women aged 40-49 years. , 2004, Journal of the National Cancer Institute.

[211]  H. Murff,et al.  Cancer risk assessment: quality and impact of the family history interview. , 2004, American journal of preventive medicine.

[212]  H. Murff,et al.  Does this patient have a family history of cancer? An evidence-based analysis of the accuracy of family cancer history. , 2004, JAMA.

[213]  E. Ostrander,et al.  Frequency of CHEK2 mutations in a population based, case–control study of breast cancer in young women , 2004, Breast Cancer Research.

[214]  Ellen Warner,et al.  Surveillance of BRCA1 and BRCA2 mutation carriers with magnetic resonance imaging, ultrasound, mammography, and clinical breast examination , 2004, JAMA.

[215]  H. D. de Koning,et al.  Efficacy of MRI and mammography for breast-cancer screening in women with a familial or genetic predisposition. , 2004, The New England journal of medicine.

[216]  W. Foulkes,et al.  Germline E-cadherin mutations in hereditary diffuse gastric cancer: assessment of 42 new families and review of genetic screening criteria , 2004, Journal of Medical Genetics.

[217]  Ellen Warner,et al.  Contralateral breast cancer in BRCA1 and BRCA2 mutation carriers. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[218]  A. Ayadi-Kaddour,et al.  Colonic adenocarcinoma and bilateral malignant ovarian sex cord tumor with annular tubules in Peutz-Jeghers syndrome. , 2004, Pathologica.

[219]  K. Offit,et al.  BRCA Mutations and Risk of Prostate Cancer in Ashkenazi Jews , 2004, Clinical Cancer Research.

[220]  C Eng,et al.  Will the real Cowden syndrome please stand up (again)? Expanding mutational and clinical spectra of the PTEN hamartoma tumour syndrome , 2004, Journal of Medical Genetics.

[221]  Julie O. Culver,et al.  Genetic Cancer Risk Assessment and Counseling: Recommendations of the National Society of Genetic Counselors , 2004, Journal of Genetic Counseling.

[222]  J. Klijn,et al.  Pathology of Ovarian Cancers in BRCA1 and BRCA2 Carriers , 2004, Clinical Cancer Research.

[223]  Susan L Neuhausen,et al.  Bilateral prophylactic mastectomy reduces breast cancer risk in BRCA1 and BRCA2 mutation carriers: the PROSE Study Group. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[224]  J. Garber,et al.  Prophylactic oophorectomy and hormone replacement therapy: protection at what price? , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[225]  B. Karlan,et al.  Cancer risks for male carriers of germline mutations in BRCA1 or BRCA2: a review of the literature. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[226]  A. Whittemore,et al.  Histopathology, FIGO Stage, and BRCA Mutation Status of Ovarian Cancers from the Gilda Radner Familial Ovarian Cancer Registry , 2004, International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists.

[227]  Holly Neibergs,et al.  Breast and ovarian cancer risks due to inherited mutations in BRCA1 and BRCA2 , 2004 .

[228]  A. Jemal,et al.  Cancer Statistics, 2004 , 2004, CA: a cancer journal for clinicians.

[229]  Thorunn Rafnar,et al.  The Icelandic founder mutation BRCA2 999del5: analysis of expression , 2004, Breast Cancer Research.

[230]  L. Strong,et al.  Novel p53 germline mutation in a patient with Li−Fraumeni syndrome , 2003, Internal medicine journal.

[231]  K. Offit,et al.  Fallopian tube and primary peritoneal carcinomas associated with BRCA mutations. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[232]  G. Reifenberger,et al.  Germline inactivation of PTEN and dysregulation of the phosphoinositol-3-kinase/Akt pathway cause human Lhermitte-Duclos disease in adults. , 2003, American journal of human genetics.

[233]  R. Langer,et al.  Influence of estrogen plus progestin on breast cancer and mammography in healthy postmenopausal women: the Women's Health Initiative Randomized Trial. , 2003, JAMA.

[234]  Kenneth Offit,et al.  Shared genetic susceptibility to breast cancer, brain tumors, and Fanconi anemia. , 2003, Journal of the National Cancer Institute.

[235]  H. Hollema,et al.  Gynecologic screening in hereditary nonpolyposis colorectal cancer. , 2003, Gynecologic oncology.

[236]  Charis Eng,et al.  PTEN: One Gene, Many Syndromes , 2003, Human mutation.

[237]  J. Ivanovich,et al.  Germline PTEN promoter mutations and deletions in Cowden/Bannayan-Riley-Ruvalcaba syndrome result in aberrant PTEN protein and dysregulation of the phosphoinositol-3-kinase/Akt pathway. , 2003, American journal of human genetics.

[238]  Adopted on March.  American Society of Clinical Oncology policy statement update: genetic testing for cancer susceptibility. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[239]  R. L. Baldwin,et al.  Improved survival in women with BRCA‐associated ovarian carcinoma , 2003, Cancer.

[240]  M. Beckmann,et al.  Cowden's disease: clinical and molecular genetic findings in a patient with a novel PTEN germline mutation , 2003, The British journal of dermatology.

[241]  J. Hopper,et al.  Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case Series unselected for family history: a combined analysis of 22 studies. , 2003, American journal of human genetics.

[242]  P. Pharoah,et al.  Prediction of pathogenic mutations in patients with early-onset breast cancer by family history , 2003, The Lancet.

[243]  A. Dutra,et al.  Differentiation of human bone marrow-derived cells into buccal epithelial cells in vivo: a molecular analytical study , 2003, The Lancet.

[244]  A. Ziegler,et al.  BRCA2 germline mutations in familial pancreatic carcinoma. , 2003, Journal of the National Cancer Institute.

[245]  C. Sotiriou,et al.  Molecular determinants of tumor differentiation in papillary serous ovarian carcinoma , 2003, Molecular carcinogenesis.

[246]  F. Couch,et al.  Oral contraceptives and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers. , 2002, Journal of the National Cancer Institute.

[247]  P. Wingo,et al.  Hormone Replacement Therapy Regimens and Breast Cancer Risk , 2002 .

[248]  J. Satagopan,et al.  Ovarian cancer risk in Ashkenazi Jewish carriers of BRCA1 and BRCA2 mutations. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

[249]  Theo van der Kwast,et al.  A BRCA1/2 mutation, high breast density and prominent pushing margins of a tumor independently contribute to a frequent false‐negative mammography , 2002, International journal of cancer.

[250]  Charles Kooperberg,et al.  Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial. , 2002, JAMA.

[251]  R. Barkardottir,et al.  The effect of a single BRCA2 mutation on cancer in Iceland , 2002, Journal of medical genetics.

[252]  Kathleen M Murphy,et al.  Evaluation of candidate genes MAP2K4, MADH4, ACVR1B, and BRCA2 in familial pancreatic cancer: deleterious BRCA2 mutations in 17%. , 2002, Cancer research.

[253]  C. Eng,et al.  The expanding role of PTEN in neoplasia: a molecule for all seasons? Commentary re: M. A. Davies, et al., Adenoviral-mediated expression of MMAC/PTEN inhibits proliferation and metastasis of human prostate cancer cells. Clin. Cancer Res., 8: 1904-1914, 2002. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

[254]  Giovanni Parmigiani,et al.  BRCAPRO validation, sensitivity of genetic testing of BRCA1/BRCA2, and prevalence of other breast cancer susceptibility genes. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[255]  J. Satagopan,et al.  Risk-reducing salpingo-oophorectomy in women with a BRCA1 or BRCA2 mutation. , 2002, The New England journal of medicine.

[256]  Susan L Neuhausen,et al.  Prophylactic oophorectomy in carriers of BRCA1 or BRCA2 mutations. , 2002, The New England journal of medicine.

[257]  L. Aaltonen,et al.  Screening E‐cadherin in gastric cancer families reveals germline mutations only in hereditary diffuse gastric cancer kindred , 2002, Human mutation.

[258]  M. J. van de Vijver,et al.  The pathology of familial breast cancer: predictive value of immunohistochemical markers estrogen receptor, progesterone receptor, HER-2, and p53 in patients with mutations in BRCA1 and BRCA2. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[259]  G. Kenter,et al.  The outcome of endometrial carcinoma surveillance by ultrasound scan in women at risk of hereditary nonpolyposis colorectal carcinoma and familial colorectal carcinoma , 2002, Cancer.

[260]  Douglas F. Easton,et al.  Polygenic susceptibility to breast cancer and implications for prevention , 2002, Nature Genetics.

[261]  Ashok R Venkitaraman,et al.  Cancer Susceptibility and the Functions of BRCA1 and BRCA2 , 2002, Cell.

[262]  P. Wingo,et al.  Hormone replacement therapy regimens and breast cancer risk(1). , 2002, Obstetrics and gynecology.

[263]  A. Leitch,et al.  Limitations of the Gail Model in the Specialized Breast Cancer Risk Assessment Clinic , 2002, The breast journal.

[264]  C Caldas,et al.  Incidence of gastric cancer and breast cancer in CDH1 (E-cadherin) mutation carriers from hereditary diffuse gastric cancer families. , 2001, Gastroenterology.

[265]  T. Sellers,et al.  Efficacy of bilateral prophylactic mastectomy in BRCA1 and BRCA2 gene mutation carriers. , 2001, Journal of the National Cancer Institute.

[266]  Douglas F Easton,et al.  BRCA1 and BRCA2 mutations in a population-based study of male breast cancer , 2001, Breast Cancer Research.

[267]  A. Wallgren,et al.  The western Swedish BRCA1 founder mutation 3171ins5; a 3.7 cM conserved haplotype of today is a reminiscence of a 1500-year-old mutation , 2001, European Journal of Human Genetics.

[268]  J. Klijn,et al.  Breast cancer after prophylactic bilateral mastectomy in women with a BRCA1 or BRCA2 mutation. , 2001, The New England journal of medicine.

[269]  S. Tsuji,et al.  Localization of a novel susceptibility gene for familial ovarian cancer to chromosome 3p22-p25. , 2001, Human molecular genetics.

[270]  M H Gail,et al.  Validating and improving models for projecting the absolute risk of breast cancer. , 2001, Journal of the National Cancer Institute.

[271]  D Spiegelman,et al.  Validation of the Gail et al. model of breast cancer risk prediction and implications for chemoprevention. , 2001, Journal of the National Cancer Institute.

[272]  B. Rosen,et al.  Prevalence and penetrance of germline BRCA1 and BRCA2 mutations in a population series of 649 women with ovarian cancer. , 2001, American journal of human genetics.

[273]  J. Fraumeni,et al.  Germ-line p53 mutations predispose to a wide spectrum of early-onset cancers. , 2001, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[274]  C. Bonaïti‐pellié,et al.  Sensitivity and predictive value of criteria for p53germline mutation screening , 2001, Journal of medical genetics.

[275]  J O Barentsz,et al.  Magnetic resonance imaging and mammography in women with a hereditary risk of breast cancer. , 2001, Journal of the National Cancer Institute.

[276]  K. Heimdal,et al.  Tamoxifen and risk of contralateral breast cancer in BRCA1 and BRCA2 mutation carriers: a case-control study , 2000, The Lancet.

[277]  E. Berns,et al.  Prognostic significance of germline BRCA2 mutations in hereditary breast cancer patients. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[278]  C. Eng.  Will the real Cowden syndrome please stand up: revised diagnostic criteria , 2000, Journal of medical genetics.

[279]  P. Porter,et al.  Breast density as a predictor of mammographic detection: comparison of interval- and screen-detected cancers. , 2000, Journal of the National Cancer Institute.

[280]  A. Patenaude,et al.  Anticipated versus actual emotional reactions to disclosure of results of genetic tests for cancer susceptibility: findings from p53 and BRCA1 testing programs. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[281]  C R Key,et al.  Biologic characteristics of interval and screen-detected breast cancers. , 2000, Journal of the National Cancer Institute.

[282]  J. Klijn,et al.  ATM-heterozygous germline mutations contribute to breast cancer-susceptibility. , 2000, American journal of human genetics.

[283]  S. Lele,et al.  Malignant Ovarian Sex Cord Tumor with Annular Tubules in a Patient with Peutz-Jeghers Syndrome: A Case Report , 2000, Modern Pathology.

[284]  I. Soubeyran,et al.  Thyroid pathologic findings in patients with Cowden disease. , 1999, Annals of diagnostic pathology.

[285]  B. Ponder,et al.  The contribution of germline BRCA1 and BRCA2 mutations to familial ovarian cancer: no evidence for other ovarian cancer-susceptibility genes. , 1999, American journal of human genetics.

[286]  J Benichou,et al.  Validation studies for models projecting the risk of invasive and total breast cancer incidence. , 1999, Journal of the National Cancer Institute.

[287]  O. Olopade,et al.  Breast cancer risk after bilateral prophylactic oophorectomy in BRCA1 mutation carriers. , 1999, Journal of the National Cancer Institute.

[288]  S. Cummings,et al.  The effect of raloxifene on risk of breast cancer in postmenopausal women: results from the MORE randomized trial. Multiple Outcomes of Raloxifene Evaluation. , 1999, JAMA.

[289]  C. Woods,et al.  Novel PTEN mutations in patients with Cowden disease: absence of clear genotype–phenotype correlations , 1999, European Journal of Human Genetics.

[290]  D. Berry,et al.  Attitudes, knowledge, and risk perceptions of women with breast and/or ovarian cancer considering testing for BRCA1 and BRCA2. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[291]  B. Ponder,et al.  High frequency of germ-line BRCA2 mutations among Hungarian male breast cancer patients without family history. , 1999, Cancer research.

[292]  D J Schaid,et al.  Efficacy of bilateral prophylactic mastectomy in women with a family history of breast cancer. , 1999, The New England journal of medicine.

[293]  H. Olsson.  Cancer risks in BRCA2 mutation carriers. , 1999, Journal of the National Cancer Institute.

[294]  A. Mes-Masson,et al.  Founder BRCA1 and BRCA2 mutations in French Canadian breast and ovarian cancer families. , 1998, American journal of human genetics.

[295]  Torn,et al.  Frequency of germline and somatic BRCA1 mutations in ovarian cancer. , 1998, Clinical cancer research : an official journal of the American Association for Cancer Research.

[296]  D. Evans,et al.  Cancer phenotype correlates with constitutional TP53 genotype in families with the Li–Fraumeni syndrome , 1998, Oncogene.

[297]  B. Ponder,et al.  Oral Contraceptives and the Risk of Hereditary Ovarian Cancer , 1998 .

[298]  N. Holtzman,et al.  Decision-making about breast cancer susceptibility testing: how similar are the attitudes of physicians, nurse practitioners, and at-risk women? , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[299]  G. Colditz,et al.  Relationship between estrogen levels, use of hormone replacement therapy, and breast cancer. , 1998, Journal of the National Cancer Institute.

[300]  A. Jonasdottir,et al.  A population study of mutations and LOH at breast cancer gene loci in tumours from sister pairs: two recurrent mutations seem to account for all BRCA1/BRCA2 linked breast cancer in Iceland. , 1998, Journal of medical genetics.

[301]  G. I. Obrams,et al.  Epidemiology and risk assessment for ovarian cancer. , 1998, Seminars in oncology.

[302]  B. Weber,et al.  BRCA1 and BRCA2: from molecular genetics to clinical medicine. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[303]  B. Biesecker,et al.  Breast cancer susceptibility genes. BRCA1 and BRCA2. , 1998, Medicine.

[304]  L. Norton,et al.  BRCA-associated breast cancer in young women. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[305]  D. Birnbaum,et al.  Mutations at BRCA1: the medullary breast carcinoma revisited. , 1998, Cancer research.

[306]  J. Fraumeni,et al.  Multiple primary cancers in families with Li-Fraumeni syndrome. , 1998, Journal of the National Cancer Institute.

[307]  R Holland,et al.  Effect of mammographic breast density on breast cancer screening performance: a study in Nijmegen, The Netherlands. , 1998, Journal of epidemiology and community health.

[308]  C. Eng.  Genetics of Cowden syndrome: through the looking glass of oncology. , 1998, International journal of oncology.

[309]  J Chang-Claude,et al.  Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. The Breast Cancer Linkage Consortium. , 1998, American journal of human genetics.

[310]  C Eng,et al.  Mutation spectrum and genotype-phenotype analyses in Cowden disease and Bannayan-Zonana syndrome, two hamartoma syndromes with germline PTEN mutation. , 1998, Human molecular genetics.

[311]  J. Ranstam,et al.  Survival of BRCA1 breast and ovarian cancer patients: a population-based study from southern Sweden. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[312]  J. Klijn,et al.  Survival and tumour characteristics of breast-cancer patients with germline mutations of BRCA1 , 1998, The Lancet.

[313]  B. Ponder,et al.  Oral contraceptives and the risk of hereditary ovarian cancer. Hereditary Ovarian Cancer Clinical Study Group. , 1998, The New England journal of medicine.

[314]  D. Berry,et al.  Determining carrier probabilities for breast cancer-susceptibility genes BRCA1 and BRCA2. , 1998, American journal of human genetics.

[315]  T Takahashi,et al.  Clinical features of ovarian cancer in Japanese women with germ-line mutations of BRCA1. , 1998, Clinical cancer research : an official journal of the American Association for Cancer Research.

[316]  Peter Devilee,et al.  BRCA1 genomic deletions are major founder mutations in Dutch breast cancer patients , 1997, Nature Genetics.

[317]  J. Ott,et al.  The role of MMAC1 mutations in early-onset breast cancer: causative in association with Cowden syndrome and excluded in BRCA1-negative cases. , 1997, American journal of human genetics.

[318]  K Offit,et al.  BRCA1 sequence analysis in women at high risk for susceptibility mutations. Risk factor analysis and implications for genetic testing. , 1997, JAMA.

[319]  D. Page,et al.  BRCA1 and BRCA2 hereditary breast carcinoma phenotypes , 1997 .

[320]  N. Day,et al.  Family history and the risk of breast cancer: A systematic review and meta‐analysis , 1997, International journal of cancer.

[321]  M. Stratton.  Pathology of familial breast cancer: differences between breast cancers in carriers of BRCA1 or BRCA2 mutations and sporadic cases , 1997, The Lancet.

[322]  F. Couch,et al.  BRCA1 mutations in women attending clinics that evaluate the risk of breast cancer. , 1997, The New England journal of medicine.

[323]  B. Weber,et al.  Founder BRCA1 and BRCA2 mutations in Ashkenazi Jews in Israel: frequency and differential penetrance in ovarian cancer and in breast-ovarian cancer families. , 1997, American journal of human genetics.

[324]  Steven Gallinger,et al.  Germline BRCA2 6174delT mutations in Ashkenazi Jewish pancreatic cancer patients , 1997, Nature Genetics.

[325]  G. Pals,et al.  A high proportion of novel mutations in BRCA1 with strong founder effects among Dutch and Belgian hereditary breast and ovarian cancer families. , 1997, American journal of human genetics.

[326]  E. Thomson,et al.  Recommendations for follow-up care of individuals with an inherited predisposition to Cancer. II. BRCA1 and BRCA2 , 1997 .

[327]  I. Lerer,et al.  The founder mutations 185delAG and 5382insC in BRCA1 and 6174delT in BRCA2 appear in 60% of ovarian cancer and 30% of early-onset breast cancer patients among Ashkenazi women. , 1997, American journal of human genetics.

[328]  A. Levine.  p53, the Cellular Gatekeeper for Growth and Division , 1997, Cell.

[329]  B. Ponder,et al.  Mutation analysis of BRCA1 and BRCA2 in a male breast cancer population. , 1997, American journal of human genetics.

[330]  A. Whittemore.  Risk of breast cancer in carriers of BRCA gene mutations. , 1997, The New England journal of medicine.

[331]  D. Evans,et al.  Li-Fraumeni syndrome--a molecular and clinical review. , 1997, British Journal of Cancer.

[332]  S. Seal,et al.  Variation of risks of breast and ovarian cancer associated with different germline mutations of the BRCA2 gene , 1997, Nature Genetics.

[333]  M. Morgan,et al.  Clinical and pathological features of ovarian cancer in women with germ-line mutations of BRCA1. , 1996, The New England journal of medicine.

[334]  C A Bodian,et al.  Lobular neoplasia: Long term risk of breast cancer and relation to other factors , 1996, Cancer.

[335]  J. Rommens,et al.  BRCA2 germline mutations in male breast cancer cases and breast cancer families , 1996, Nature Genetics.

[336]  E. Mariman,et al.  Localization of the gene for Cowden disease to chromosome 10q22–23 , 1996, Nature Genetics.

[337]  M. King,et al.  Growth retardation and tumour inhibition by BRCA1 , 1996, Nature Genetics.

[338]  R. Bennett,et al.  Recommendations for standardized human pedigree nomenclature. Pedigree Standardization Task Force of the National Society of Genetic Counselors. , 1995, American journal of human genetics.

[339]  R. Eeles.  Germline mutations in the TP53 gene. , 1995, Cancer surveys.

[340]  S. Seal,et al.  Localization of a breast cancer susceptibility gene, BRCA2, to chromosome 13q12-13. , 1994, Science.

[341]  N Risch,et al.  Autosomal dominant inheritance of early‐onset breast cancer. Implications for risk prediction , 1994, Cancer.

[342]  D. Easton,et al.  Risks of cancer in BRCA1-mutation carriers , 1994, The Lancet.

[343]  A. Craft,et al.  Prevalence and diversity of constitutional mutations in the p53 gene among 21 Li-Fraumeni families. , 1994, Cancer research.

[344]  M. Osborne,et al.  Current management of lobular carcinoma in situ of the breast. , 1994, Oncology.

[345]  M. Slattery,et al.  A comprehensive evaluation of family history and breast cancer risk. The Utah Population Database. , 1993, JAMA.

[346]  J. Manson,et al.  Family history, age, and risk of breast cancer. Prospective data from the Nurses' Health Study. , 1993, JAMA.

[347]  M. Piver,et al.  Primary peritoneal carcinoma after prophylactic oophorectomy in women with a family history of ovarian cancer. A report of the gilda radner familial ovarian cancer registry , 1993, Cancer.

[348]  K. Kinzler,et al.  The multistep nature of cancer. , 1993, Trends in genetics : TIG.

[349]  L. Strong,et al.  Segregation analysis of cancer in families of childhood soft-tissue-sarcoma patients. , 1992, American journal of human genetics.

[350]  B. Vogelstein,et al.  Inherited p53 gene mutations in breast cancer. , 1992, Cancer research.

[351]  N. Golden,et al.  in Women with , 1992 .

[352]  D. Lane,et al.  Cancer. p53, guardian of the genome. , 1992, Nature.

[353]  C. Slomski.  The Breast Cancer Prevention Trial. , 1992, Journal of the American Medical Women's Association.

[354]  J. Fraumeni,et al.  Follow-up study of twenty-four families with Li-Fraumeni syndrome. , 1991, Cancer research.

[355]  G. Lenoir,et al.  Familial breast-ovarian cancer locus on chromosome 17q12-q23 , 1991, The Lancet.

[356]  H T Lynch,et al.  Hereditary breast cancer. , 1991, Annals of medicine.

[357]  M. King,et al.  Linkage of early-onset familial breast cancer to chromosome 17q21. , 1990, Science.

[358]  L. Strong,et al.  Germ line p53 mutations in a familial syndrome of breast cancer, sarcomas, and other neoplasms. , 1990, Science.

[359]  B. Vogelstein,et al.  A genetic model for colorectal tumorigenesis , 1990, Cell.

[360]  M. Gail,et al.  Projecting individualized probabilities of developing breast cancer for white females who are being examined annually. , 1989, Journal of the National Cancer Institute.

[361]  W. Blattner,et al.  A cancer family syndrome in twenty-four kindreds. , 1988, Cancer research.

[362]  D Mukherjee,et al.  Head circumference reference data: birth to 18 years. , 1987, Pediatrics.

[363]  F. Arwert,et al.  The Cowden syndrome: a clinical and genetic study in 21 patients , 1986, Clinical genetics.

[364]  A. Mehregan,et al.  The dermatopathology of Cowden's syndrome * , 1979, The British journal of dermatology.

[365]  M. Wolf,et al.  Cowden's disease: a cutaneous marker of breast cancer. , 1978, Cancer.

[366]  A. Mehregan,et al.  Trichilemmomas in Cowden's disease. , 1977, JAMA.

[367]  J. Fraumeni,et al.  Soft-tissue sarcomas, breast cancer, and other neoplasms. A familial syndrome? , 1969, Annals of internal medicine.

[368]  K. Lloyd,et al.  Cowden's disease. A possible new symptom complex with multiple system involvement. , 1963 .